Phase I first-in-human study Evaluating the Safety, Tolerability Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
The goal of this clinical research study is to learn about the safety of giving AMG 330 to patients with acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). Researchers want to learn the highest tolerable dose that can be given. This is the first study using AMG 330 in humans.
Disease Group: Leukemia
Treatment Agent: AMG 330
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Amgen Inc.
IRB Review and Approval Date: 10/14/2015
Recruitment Status: Open
Projected Accrual: 70
Information and next steps
For general questions about clinical trials: